A detailed history of Exodus Point Capital Management, LP transactions in Mannkind Corp stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 85,199 shares of MNKD stock, worth $505,230. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,199
Previous 203,511 58.14%
Holding current value
$505,230
Previous $1.06 Million 49.53%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$5.01 - $6.7 $592,743 - $792,690
-118,312 Reduced 58.14%
85,199 $536,000
Q2 2024

Aug 13, 2024

SELL
$4.05 - $5.43 $533,656 - $715,494
-131,767 Reduced 39.3%
203,511 $1.06 Million
Q1 2024

May 14, 2024

BUY
$3.25 - $5.27 $705,003 - $1.14 Million
216,924 Added 183.28%
335,278 $1.52 Million
Q3 2023

Nov 09, 2023

BUY
$3.91 - $5.45 $78,282 - $109,114
20,021 Added 20.36%
118,354 $489,000
Q2 2023

Aug 10, 2023

SELL
$3.72 - $4.79 $1.64 Million - $2.12 Million
-441,653 Reduced 81.79%
98,333 $400,000
Q1 2023

May 11, 2023

BUY
$3.95 - $5.63 $1.17 Million - $1.67 Million
295,953 Added 121.28%
539,986 $2.21 Million
Q4 2022

Feb 13, 2023

SELL
$3.02 - $5.37 $33,938 - $60,348
-11,238 Reduced 4.4%
244,033 $1.29 Million
Q3 2022

Nov 10, 2022

BUY
$2.99 - $4.35 $328,128 - $477,377
109,742 Added 75.41%
255,271 $789,000
Q2 2022

Aug 19, 2022

BUY
$2.67 - $4.77 $255,599 - $456,632
95,730 Added 192.23%
145,529 $554,000
Q1 2022

May 13, 2022

BUY
$2.62 - $4.45 $130,473 - $221,605
49,799 New
49,799 $183,000
Q3 2021

Nov 15, 2021

SELL
$3.89 - $5.48 $106,099 - $149,467
-27,275 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.61 - $5.45 $98,462 - $148,648
27,275 New
27,275 $149,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.53B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.